Fundraising Fox
Cambridge · Seed–Late Stage · 13 people tracked
Find your way into AbbVie
Each arrow is one introduction. Sign up to fill in the first one.
Ask Kobe to introduce you to Claire Leurent
You →Kobe · together at Johnson & Johnson →Claire
Ask Jamie Chen to introduce you to Shwen Gwee
You →Jamie · together at PharmStars →Shwen
Ask Sam Okafor to introduce you to Christina Vorvis
You →Sam · together at Fitango Health →Christina
- Melissa Lokugamage425 people can intro you
- Kevin Ho386 people can intro you
- Shawna Frazier267 people can intro you
Sign up to find every way you can get introduced to AbbVie
- Your email: who you already know at AbbVie, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the AbbVie team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Very early discovery and preclinical therapeutics company-creation partner tightly integrated with AbbVie R&D, offering founders direct in-house expertise in oncology, immunology, neuroscience and development/commercial infrastructure.
Team · 13 people
from curated & public directories
Founder mafia
The AbbVie mafia →17 people who came through AbbVie went on to found or lead other companies.
What they invest in
from 16 of 17 portfolio companiesBiotech ×16Healthtech ×5Medical Devices ×3AI & Machine Learning ×2Longevity ×2Deep Tech ×1Digital Health ×1
HQs:United States×9Italy×1
Investments · 17 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 12020 · 22018 · 32017 · 311 dated
Enanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need.
Biotech
Jay R. Luly(President, Director and Chief Executive Officer)Yat Sun Or(Chief Scientific Officer)Scott T. Rottinghaus(Chief Medical Officer)inMatthew P. Kowalsky(Chief Legal Officer and Corporate Secretary)Tara L. Kieffer(Chief Product Strategy Officer)inBrendan Luu(Chief Business Officer)in
Co-investorsSaints CapitalSofinnova Ventures
Exicure is a publicly-traded holding company that previously developed nucleic acid therapies and has since divested its historical biotechnology assets; it is now pursuing growth through acquisitions and partnerships, including a recent investment in GPCR Therapeutics USA, which is developing small molecule therapies for blood cancers and multiple myeloma.
BiotechSkokie, US
Chad A. Mirkin(Director)C. Shad Thaxton(Director)David A. Giljohann(Chief Executive Officer)inDavid S. Snyder(Chief Financial Officer)inPercy Van Crocker, Jr.(Vice President, Commercial Development)
BoardJay Venkatesan(Director)
Co-investorsInnovation EndeavorsPurple Arch VenturesRockPort Capital Partners
Light Horse Therapeutics is a drug discovery company applying scientific expertise and innovation to advance healthcare through collaborative development.
AI & Machine LearningBiotechMedical Devices
Co-investorsTaiho Ventures, LLCMubadala CapitalVersant Ventures
Aquinnah Pharmaceuticals develops oral small-molecule therapeutics targeting pathologic biomolecular condensates, such as stress granules formed by RNA-binding proteins, to slow neurodegenerative diseases including ALS and Alzheimer's disease.
BiotechHealthtechLongevity
Benjamin Wolozin(CSO & Co-founder)
Co-investorsPfizer Venture Investments
Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases.
BiotechHealthtech
Co-investorsDementia Discovery FundEisai Innovation, Inc.McCarthy CapitalMRL Ventures FundSV Health InvestorsBridge Investments+9 more
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)in
BoardMargarita Chavez(Director)inEran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)in
Co-investorsAgent CapitalAju IB Invesment CorporationAnzu PartnersGrazia Equity GmbHHealthCapMRL Ventures Fund+3 more
Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.
BiotechHealthtechMilan, IT
Co-investorsSofinnova PartnersIndaco Venture PartnersRoche Venture FundJDRF T1D Fund
Leal Therapeutics is a company focused on CNS (central nervous system) disorders, drawing on academic and drug-development experience in neurology and neurodegenerative disease.
BiotechHealthtechMedical DevicesWorcester, US
Asa Abeliovich(CEO & Founder, Director)
Co-investorsOrbiMedSV Health InvestorsNewpath Partners
Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration.
BiotechHealthtechLongevity
Irene Griswold-Prenner(Founder & Chief Executive Officer)in
Co-investorsDementia Discovery FundMission BiocapitalSofinnova PartnersSV Health InvestorsMission Bay Capital
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
Co-investorsHatteras Venture PartnersIllumina VenturesM VenturesMC Healthcare VenturesPappas CapitalSV Health Investors+2 more
BiotechLexington, US
Victoria M. Richon(Executive Officer, Director)in
BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)
Co-investorsAvego BioScience CapitalOUP (Osage University Partners)Peregrine VenturesDeerfield Management CompanyJJDCNovartis Venture Fund+4 more
Stylus Medicine develops in vivo genetic medicines using engineered recombinases, with initial focus on creating CAR-T therapies delivered via lipid nanoparticles for oncology, autoimmune, and genetic diseases.
BiotechDigital HealthMedical Devices
Michael C. Bassik, Ph.D.(Scientific Founder)Emile Nuwaysir, Ph.D.(Chairman & Chief Executive Officer)inJason Fontenot, Ph.D.(Chief Scientific Officer)
Co-investorsBrainstorm VenturesCALIFORNIA INNOVATIONKhosla VenturesNeva Sgr.RA CapitalTachyon Ventures
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets.
AI & Machine LearningBiotechDeep TechDurham, US
Mark A. Hallen(Executive Officer, Director)inMarcel Frenkel(Executive Officer, Director)Damien Petty(Director)inJia Wei Xu(Director)
Co-investorsCape Fear BioCapitalDFJ DragonFundDraper AssociatesDuke Capital PartnersHatteras Venture PartnersAlexandria+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Lodo TherapeuticsMagnolia NeurosciencesParagen BioPetra Pharma
Exits · 3
2 IPOs · 1 acquisitionsEnanta PharmaceuticalsNASDAQ: ENTAExicureNASDAQ: XCURCarawayacq. by Merck
Portfolio news
latest coverage across their companiesIPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Enanta Pharmaceuticals | 6.4% | $14.00 | Mar 2013 | $15M |
| Exicure | — | $3.00 | Jan 2018 | $5.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has AbbVie made?
- AbbVie has 17 tracked investments, 3 of which have exited, including 3 dated in the last 24 months.
- What stage does AbbVie invest at?
- AbbVie invests at the Seed, Series A, Late Stage stages.
- What is AbbVie's typical check size?
- AbbVie typically writes checks of $300K – $3M.
- What sectors does AbbVie focus on?
- AbbVie focuses on Biotech.
- Where is AbbVie located?
- AbbVie is headquartered in Cambridge, US.
- Does AbbVie lead rounds?
- AbbVie typically participates in rounds rather than leading them.
Co-investors · 6
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Hatteras Venture Partners is a venture capital firm focused on early-stage life sciences and healthcare companies, backing therapeutics, diagnostics, and businesses aiming to transform healthcare delivery and innovation.
M Ventures is the corporate venture arm of Merck KGaA based in Darmstadt, Germany, operating from offices in Amsterdam, the US, and Israel. The firm invests globally across early-stage companies and spin-offs in areas aligned with Merck's core business, taking active roles in portfolio company development.
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
Morpheus Ventures is a venture capital fund that backs early-stage companies and supports founders through the challenges of scaling toward hyper-growth.
Agent Capital is a healthcare venture capital firm that makes direct equity investments in novel, differentiated therapeutics and treatments addressing unmet patient needs, from preclinical through commercial stages.
Firms observed investing alongside AbbVie, from public investor directories. Shared companies are the overlap with AbbVie's recorded portfolio.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.